Vcanbio Cell & Gene Engineering Corp., Ltd

Vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SS) is a Tianjin, China-based biotechnology company founded in 1992 and listed on the Shanghai Stock Exchange, operating across three core segments: precision prevention, precision diagnosis, and cell therapy. The company specializes in the preparation and cryopreservation of a broad range of stem cells — including umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells — as well as immune cells, positioning itself as a leading cell banking service provider in China. Beyond cell storage, Vcanbio offers comprehensive genetic testing services such as non-invasive prenatal screening, pharmacogenomic testing, and disease susceptibility analysis, while also developing and commercializing in vitro diagnostic raw materials, reagents, medical devices, and biological products including genes, proteins, and antibodies. With approximately 2,200 full-time employees and a market capitalization of approximately CNY 8.8 billion, Vcanbio is strategically building an integrated "precision medicine" industry chain to provide health management services spanning the entire human life cycle.